Phaseline

Targets › PAUF

PAUF (Pancreatic adenocarcinoma up-regulated factor): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Functions as a lectin that binds to selective commensal dental plaque bacteria, such as Streptococcus vestibularis. Contributes to maintain homeostasis in the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism. (UniProt, Q96DA0)

Open in Phaseline: the race on PAUF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Prestige BiopharmaPBP1510
Anti-PAUF monoclonal antibody
PAUFPhase 1Pancreatic CancerDec 2026

Conditions

Pancreatic Cancer (1)

Modalities

small molecule (1)

Companies

Prestige Biopharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.